Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 6/20 | 1.00 |
| ▸ | MMP9 | P14780 | 6/20 | 1.00 |
| ▸ | MMP12 | P39900 | 4/20 | 1.00 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.49 |
| ▸ | MMP1 | P03956 | 3/20 | 0.48 |
| ▸ | MMP13 | P45452 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MMP3 | P08254 | 1/20 | 0.43 |
| ▸ | MMP7 | P09237 | 1/20 | 0.43 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5997913 | 1.00 | MMP2 (1.00) | MMP2MMP9MMP12ADAM17MMP1 | |
| SCHEMBL8403058 | 0.89 | MMP2 (0.80) | MMP2MMP9MMP12ADAM17MMP1 | |
| SCHEMBL8065994 | 0.89 | MMP2 (0.80) | MMP2MMP9MMP12ADAM17MMP1 | |
| SCHEMBL14095009 | 0.85 | MMP2 (0.74) | MMP2MMP9MMP12ADAM17MMP1 | |
| SCHEMBL14068076 | 0.85 | MMP2 (0.74) | MMP2MMP9MMP12ADAM17MMP1 | |
| SCHEMBL5998380 | 0.85 | MMP2 (0.73) | MMP2MMP9MMP12ADAM17MMP1 | |
| SCHEMBL5998377 | 0.85 | MMP2 (0.73) | MMP2MMP9MMP12ADAM17MMP1 | |
| SCHEMBL2378490 | 0.84 | MMP2 (0.72) | MMP2MMP9MMP12ADAM17MMP1 | |
| SCHEMBL7734890 | 0.84 | MMP2 (0.74) | MMP2MMP9MMP12ADAM17MMP1 | |
| SCHEMBL3043179 | 0.84 | MMP2 (0.72) | MMP2MMP9MMP12ADAM17MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060014835-A1 | Therapeutic agent for chronic obstructive pulmonary disease | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-19 | — | — | US | claimed |
| US-20050165112-A1 | Therapeutic agent for inflammatory intestinal diseases containing hydroxamic acid compound as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-07-28 | — | — | US | claimed |
| EP-1552824-A1 | THERAPEUTIC AGENT FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-07-13 | — | — | EP | claimed |
| WO-2005039638-A2 | THERAPEUTIC AGENT FOR HEART FAILURE COMPRISING AN ANGIOTENSIN II RECEPTOR ANTAGONIST AND A MATRIX METALLOPROTEINASE INHIBITOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-05-06 | — | — | WO | claimed |
| EP-1510209-A1 | THERAPEUTIC AGENT FOR INFLAMMATORY INTESTINAL DISEASES CONTAINING HYDROXAMIC ACID COMPOUND AS ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-03-02 | — | — | EP | claimed |
| US-20040242694-A1 | administering N-hydroxy-5-hydroxy-2(S)-methyl-4(S)-(4-phenoxybenzoyl)aminopentanamide or derivatives for treating /preventing cardiac failure and/or cardiac hypertrophy | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-12-02 | — | — | US | claimed |
| US-20040198831-A1 | Remedial agent for arthrosis deformans | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-10-07 | — | — | US | claimed |
| EP-1421934-A1 | REMEDIAL AGENT FOR ARTHROSIS DEFORMANS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-05-26 | — | — | EP | claimed |
| EP-1419767-A1 | REMEDIAL AGENT FOR CARDIAC FAILURE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-05-19 | — | — | EP | claimed |
| US-20040068015-A1 | Remedies for diseases due to stenotic lesions of blood vessel | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-04-08 | — | — | US | claimed |
| EP-1275385-A1 | REMEDIES FOR DISEASES DUE TO STENOTIC LESIONS OF BLOOD VESSEL | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-01-15 | — | — | EP | claimed |
| US-6420427-B1 | PREVENTION AND/OR TREATMENT OF RHEUMATOID DISEASES, ARTHROSTEITIS, UNUSUAL BONE RESORPTION, OSTEOPOROSIS, PERIODONTITIS, INTERSTITIAL NEPHRITIS, ARTERIOSCLEROSIS, PULMONARY EMPHYSEMA, CIRRHOSIS, CORNEA INJURY | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-07-16 | — | — | US | claimed |
| EP-1024134-A1 | AMINOBUTANOIC ACID DERIVATIVES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2000-08-02 | — | — | EP | claimed |
| US-20060014835-A1 | Therapeutic agent for chronic obstructive pulmonary disease | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-19 | — | — | US | disclosed |
| US-20050165112-A1 | Therapeutic agent for inflammatory intestinal diseases containing hydroxamic acid compound as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-07-28 | — | — | US | disclosed |
| EP-1552824-A1 | THERAPEUTIC AGENT FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-07-13 | — | — | EP | disclosed |
| US-20040068015-A1 | Remedies for diseases due to stenotic lesions of blood vessel | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-04-08 | — | — | US | disclosed |
| EP-1275385-A1 | REMEDIES FOR DISEASES DUE TO STENOTIC LESIONS OF BLOOD VESSEL | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-01-15 | — | — | EP | disclosed |
| US-6420427-B1 | PREVENTION AND/OR TREATMENT OF RHEUMATOID DISEASES, ARTHROSTEITIS, UNUSUAL BONE RESORPTION, OSTEOPOROSIS, PERIODONTITIS, INTERSTITIAL NEPHRITIS, ARTERIOSCLEROSIS, PULMONARY EMPHYSEMA, CIRRHOSIS, CORNEA INJURY | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-07-16 | — | — | US | disclosed |
| EP-1024134-A1 | AMINOBUTANOIC ACID DERIVATIVES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2000-08-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165112-A1 | Therapeutic agent for inflammatory intestinal diseases containing hydroxamic acid compound as active ingredient | SI, SLC10A2, FABP2 | MMP2 173/4885MMP9 89/4885MMP12 38/4885 |
| US-20040198831-A1 | Remedial agent for arthrosis deformans | MMP1, MMP3, MMP11 | MMP2 14/4885MMP9 10/4885MMP12 20/4885 |
| US-20040068015-A1 | Remedies for diseases due to stenotic lesions of blood vessel | MMP11, MMP1, MMP8 | MMP2 19/4885MMP9 4/4885MMP12 23/4885 |
| US-20040242694-A1 | administering N-hydroxy-5-hydroxy-2(S)-methyl-4(S)-(4-phenoxybenzoyl)aminopentanamide or derivatives for treating /preventing cardiac failure and/or cardiac hypertrophy | TNNT2, NPR1, MMP1 | MMP2 20/4885MMP9 12/4885MMP12 65/4885 |
| US-20060014835-A1 | Therapeutic agent for chronic obstructive pulmonary disease | HAO2, MMP8, HCAR2 | MMP2 23/4885MMP9 139/4885MMP12 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.